NCT02879162

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

A Phase II Study of Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

The standard or usual treatment for this disease may be chemotherapy or other types of treatment to slow the spread of the disease and relieve some symptoms of this cancer.

Detailed description

Durvalumab is a new type of drug for many types of cancer. Laboratory tests show that it works by allowing the immune system to detect cancer and stimulate the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. Durvalumab has been shown to shrink tumours in animals and has been studied in 5000 people and seems promising but it is not clear if it can offer better results than standard treatment alone. Tremelimumab is a new type of drug for various types of cancers. It works in a similar way to durvalumab and may improve the effect of durvalumab. This may also help slow the growth of the cancer cells or may cause cancer cells to die. Tremelimumab has been shown to shrink tumours in animals and has been studied in 1500 people and seems promising but it is not clear if it can offer better results than standard treatment alone when used with durvalumab Combinations of durvalumab and tremelimumab have also been studied and when combined have been shown to increase tumour shrinkage in animals compared to either drug alone. While the combination has been studied in 250 people, it is not clear if it can offer better results than standard treatment.

Conditions

• Advanced Rare Tumours

Interventions

Type	Name	Description
DRUG	Durvalumab
DRUG	Tremelimumab

Timeline

• Start date: 2016-12-14
• Primary completion: 2021-06-20
• Completion: 2025-01-29
• First posted: 2016-08-25
• Last updated: 2025-03-07
• Results posted: 2025-02-17

Locations

13 sites across 1 country: Canada